$DHR (Danaher Corp.)

$DHR {{ '2015-07-23T11:50:16+0000' | timeago}} • Announcement

$DHR 2Q15 PR: Diluted EPS was $0.97 vs. $0.95 in 2Q14. Diluted average common shares outstanding were 719.6MM vs. 715.6MM in 2Q14. Beginning with 3Q15 results, recently divested Communications Business will be reclassified to discontinued operations for all prior periods, resulting in a $0.03 reduction in adjusted diluted net EPS for 1H15.

$DHR {{ '2017-12-14T14:05:07+0000' | timeago}} • Announcement

$DHR initiated its 2018 outlook ahead of its annual investor and analyst meeting to be held in New York City. The company sees 2018 EPS of $3.50-3.60 and adjusted EPS of $4.25-4.35, which assumes non-GAAP core revenue growth of 3.5-4%.

$DHR {{ '2017-12-05T22:21:52+0000' | timeago}} • Announcement

$DHR has approved a regular quarterly dividend of $0.14 per share payable on January 26, 2018 to holders of record on December 29, 2017.

$DHR {{ '2017-11-28T14:47:34+0000' | timeago}} • Announcement

$DHR BoD appointed Joakim Weidemanis to the position of Executive Vice President, with responsibility for the company's Product Identification and Water Quality platforms. He will continue to report directly to Thomas P. Joyce Jr., President and CEO.

$DHR {{ '2017-10-23T14:52:10+0000' | timeago}} • Webcast

$DHR's free cash flow for 3Q17 grew more than 20% YoY, resulting in a net income conversion ratio of over 160%. The company now anticipates double-digit free cash flow growth in 2017. In terms of M&A, the company closed five transactions so far this year, totaling more than $100MM of spend.

$DHR {{ '2017-10-19T12:59:49+0000' | timeago}} • Announcement

$DHR raised its FY17 guidance, now expecting non-GAAP EPS to lie in the range of $3.96 to $4.00, compared to the earlier guided range of $3.90 to $3.97. For 4Q17, non-GAAP EPS to range $1.12 to $1.16. On GAAP basis, EPS to be in the range of $3.23 to $3.27 for FY17 and $0.94 to $0.98 for 4Q17.

$DHR {{ '2017-10-19T12:54:43+0000' | timeago}} • Announcement

$DHR has successfully transformed itself into a healthcare company with broader presence in the healthcare and dental markets. With its aggressive acquisition strategy being a strong profit churner, the company saw half of its revenue growth in its recent quarter coming from the acquisitions. Revenue for 3Q17 grew 9.5% YoY, with profit growing 45%.

$DHR {{ '2017-10-19T11:32:00+0000' | timeago}} • Infographic

$DHR Danaher Corp. Earnings AlphaGraphic: Q3 2017 Highlights

$DHR {{ '2017-09-12T20:31:22+0000' | timeago}} • Announcement

$DHR said its BoD declared a regular quarterly dividend of $0.14 per share. The dividend is payable on October 27, 2017 to shareholders of record on September 29, 2017.

$DHR {{ '2017-07-20T15:06:40+0000' | timeago}} • Webcast

With nearly $900MM of free cash flow and strong conversion in 2Q17, $DHR is optimistic on further acqusitions. Adding to its strong cash flow, $DHR has $500MM to $1Bil worth of opportunities slated for 2H17. Notably, the company's two most recent large acquisitions, Pall and Cepheid, continues to perform well and became part of the core revenue.

$DHR {{ '2017-07-20T13:00:10+0000' | timeago}} • Announcement

For 3Q17, $DHR sees its GAAP EPS to range from $0.74 to $0.78 and non-GAAP EPS to range from $0.92 to $0.96. For FY17, GAAP EPS to range from $3.16 to $3.23 and non-GAAP EPS to range from $3.90 to $3.97.

$DHR {{ '2017-07-20T12:56:52+0000' | timeago}} • Announcement

$DHR, a science and technology company, reported a 15% YoY drop in net earnings for 2Q17 to $557.3MM, or $0.79 per share. Earnings, adjusted for one-time gains and costs, grew 10% to $0.99 per share. Sales rose 6% to $4.5Bil.

$DHR {{ '2017-07-20T12:12:31+0000' | timeago}} • Infographic

$DHR Danaher Corp. Earnings AlphaGraphic: Q2 2017 Highlights

$DHR {{ '2017-06-20T13:47:35+0000' | timeago}} • Announcement

$DHR's subsidiary DH Europe Finance priced an offering of EUR250MM of floating rate senior notes due 2022 at an offering price of 100.147% of the principal amount; and EUR600MM of 1.200% senior notes due 2027 at an offering price of 99.682% of the principal amount. The offering is expected to close on June 30, 2017.

$DHR {{ '2017-04-20T12:58:57+0000' | timeago}} • Webcast

$DHR is confident about its position in China across all of its five platforms and the opportunities ahead for sustained double-digit growth performance. Dental business continues to drive consistent double-digit growth in each quarter for quite sometime. $DHR added that water quality business had good performance so far this year in China.

$DHR {{ '2017-04-20T10:21:58+0000' | timeago}} • Announcement

$DHR expects 2Q17 EPS of $0.77-0.80 and adjusted EPS of $0.95-0.98. For 2017, the company still sees EPS of $3.13-3.23 and adjusted EPS of $3.85-3.95. Through focused execution across the portfolio, and with Business System continuing to serve as foundation, $DHR sees tremendous opportunities to deliver long-term value creation.

$DHR {{ '2017-04-20T10:19:32+0000' | timeago}} • Announcement

$DHR reported a drop in 1Q17 earnings hurt by higher costs and expenses as well as last year's gain on sale of investments. Net income fell to $506.1MM or $0.72 per share from $758.4MM or $1.09 per share last year. Sales grew to $4.21Bil from $3.92Bil. Adjusted EPS increased to $0.85 from $0.79.

$DHR {{ '2017-02-22T12:54:51+0000' | timeago}} • Announcement

$DHR said it has appointed Raymond Stevens to its BoD. Stevens is currently Provost Professor of Biological Sciences and Chemistry, and Director of The Bridge Institute, at the University of Southern California.

$DHR {{ '2017-01-31T19:38:32+0000' | timeago}} • Webcast

In Life Sciences, $DHR’s reported revenue was up 6% and core revenue grew 4% during 4Q16. In Diagnostics, reported revenue increased 11% and core revenue increased 3%. In the Dental segment, reported and core revenues increased 50BP. In Environmental & Applied Solutions, reported revenue grew 3.5% with core revenue up 4%.

$DHR {{ '2017-01-31T19:28:14+0000' | timeago}} • Webcast

In 4Q16, $DHR’s sales grew 6% with core revenue increasing 3.5%. The impact of currency translation decreased revenues by 1.5% while acquisitions increased revenues by 4%. High-growth markets revenue was up high single digits. Developed market core revenues were up low single digits, led by growth in the US and Western Europe.

$DHR {{ '2017-01-31T14:15:10+0000' | timeago}} • Announcement

$DHR expects 1Q17 EPS of $0.64-0.67 and adjusted EPS of $0.82-0.85. For the full year 2017, $DHR predicts EPS of $3.13-3.23 and adjusted EPS of $3.85-3.95.

Recent Transcripts

AZO (AutoZone, Inc.)
Tuesday, December 5 2017 - 3:00pm
VJET (Voxeljet AG)
Friday, November 10 2017 - 1:30pm
ENDP (Endo International plc)
Thursday, November 9 2017 - 9:30pm
VRML (Vermillion, Inc.)
Wednesday, November 8 2017 - 9:30pm
ROK (Rockwell Automation Inc.)
Wednesday, November 8 2017 - 1:30pm
INTT (inTEST Corp.)
Thursday, November 2 2017 - 9:00pm
BLDP (Ballard Power Systems Inc.)
Thursday, November 2 2017 - 3:00pm
RXN (Rexnord Corporation)
Thursday, November 2 2017 - 12:00pm
FLT (FleetCor Technologies, Inc.)
Wednesday, November 1 2017 - 9:00pm
WNC (Wabash National Corp.)
Wednesday, November 1 2017 - 2:00pm
LBY (Libbey Inc.)
Tuesday, October 31 2017 - 3:00pm
CGNX (Cognex Corporation)
Monday, October 30 2017 - 9:00pm
RTEC (Rudolph Technologies Inc.)
Monday, October 30 2017 - 8:30pm
ROP (Roper Technologies, Inc.)
Monday, October 30 2017 - 12:30pm
GILD (Gilead Sciences Inc.)
Thursday, October 26 2017 - 8:30pm
BMY (Bristol-Myers Squibb Company)
Thursday, October 26 2017 - 2:30pm
AMGN (Amgen Inc)
Wednesday, October 25 2017 - 9:00pm
WAT (Waters Corporation)
Tuesday, October 24 2017 - 12:00pm
WBC (WABCO Holdings Inc.)
Thursday, October 19 2017 - 1:00pm
DHR (Danaher Corp.)
Thursday, October 19 2017 - 12:00pm

AlphaGraphics you may like